Peptide-mediated cellular uptake of cryptophane

Bioconjugate Chemistry

Volumn 19, Issue 11, 2008, Pages 2129-2135

  Seward, Garry K ^a   Wei, Qian ^a   Dmochowski, Ivan J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSENSORS; CELL CULTURE; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

CATIONICS; CELL LINES; CELL-PENETRATING PEPTIDE; CELLULAR DELIVERY; CELLULAR UPTAKE; CRYPTOPHANE; CRYPTOPHANE-A; FUNCTIONALIZED; HIGH AFFINITY; HUMAN CANCER;

PEPTIDES;

ARGINYLGLYCYLASPARTIC ACID; CELL PENETRATING PEPTIDE; CRYPTOPHANE; INTEGRIN RECEPTOR; ORGANIC COMPOUND; UNCLASSIFIED DRUG; XENON;

ARTICLE; BIOSENSOR; CANCER CELL CULTURE; CELL LINE; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONJUGATION; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PEPTIDE SYNTHESIS; PROTEIN TARGETING;

EID: 56749179070     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc8002265     Document Type: Article

References (54)

1. Degani, H., Gusis, V., Weinstein, D., Feilds, S., and Strano, S. (1997) Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat. Med. 3, 780-782.
2. Foster-Gareau, P., Heyn, C., Alejski, A., and Rutt, B. K. (2003) Imaging single mammalian cells with a 1.5 T clinical MRI scanner. Magn. Reson. Med. 49, 968-971.
3. 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res. 66, 10855-10860.
4. Hopkins, S. R., Levin, D. L., Emami, K., Kadlecek, S., Yu, J., Ishii, M., and Rizi, R. R. (2007) Advances in magnetic resonance imaging of lung physiology. J. Appl. Physiol. 102, 1244-1254.
5. Mugler, J. P., Driehuys, B., Brookeman, J. R., Cates, G. D., Berr, S. S., Bryant, R. G., Daniel, T. M., deLange, E. E., Downs, J. H., Erickson, C. J., Happer, W., Hinton, D. P., Kassel, N. F., Maier, T., Phillips, C. D., Saam, B. T., Sauer, K. L., and Wagshul, M. E. (1997) MR imaging and spectroscopy using hyperpolarized Xe-129 gas: Preliminary human results. Magn. Reson. Med. 37, 809-815.
6. Spence, M. M., Rubin, S. M., Dimitrov, I. E., Ruiz, E. J., Wemmer, D. E., Pines, A., Yao, S. Q., Tian, F., and Schultz, P. G. (2001) Functionahzed xenon as a biosensor. Proc. Natl. Acad. Sci. U.S.A. 98, 10654-10657.
7. Collet, A. (1996) Cryptophanes. Comp. Supramol. Chem. 2, 325-365.
8. Hill, P. A., Wei, Q., Eckenhoff, R. G., and Dmochowski, I. J. (2007) Thermodynamics of xenon binding to cryptophane in water and human plasma. J. Am. Chem. Soc. 129, 9262-9263.
9. Spence, M. M., Ruiz, E. J., Rubin, S. M., Lowery, T. J., Winssinger, N., Schultz, P. G., Wemmer, D. E., and Pines, A. (2004) Development of a functionahzed xenon biosensor. J. Am. Chem. Soc. 126, 15287-15294.
10. Wei, Q., Seward, G. K., Hill, P. A., Patton, B., Dimitrov, I. E., Kuzma, N. N., and Dmochowski, I. J. (2006) Designing Xe-129 NMR biosensors for matrix metalloproteinase detection. J. Am. Chem. Soc. 128, 13274-13283.
11. Spence, M. M., Rubin, S. M., Dimitrov, I. E., Ruiz, E. J., Wemmer, D. E., Pines, A., Yao, S. Q., Tian, F., and Schultz, P. G. (2001) Functionahzed xenon as a biosensor. Proc. Natl. Acad. Sci. U.S.A. 98, 10654-10657.
12. Lowery, T. J., Garcia, S., Chavez, L., Ruiz, E. J., Wu, T., Brotin, T., Dutasta, J. P., King, D. S., Schultz, P. G., Pines, A., and Wemmer, D. E. (2006) Optimization of xenon biosensors for detection of protein interactions. ChemBioChem 7, 65-73.
13. Ruiz, E. J., Sears, D. N., Pines, A., and Jameson, C. J. (2006) Diastereomeric Xe chemical shifts in tethered cryptophane cages. J. Am. Chem. Soc. 128, 16980-16988.
14. Hilty, C., Lowery, T. J., Wemmer, D. E., and Pines, A. (2006) Spectrally resolved magnetic resonance imaging of a xenon biosensor. Angew. Chem., Int. Ed. 45, 70-73.
15. Huber, G., Brotin, T., Dubois, L., Desvaux, H., Dutasta, J. P., and Berthault, P. (2006) Water soluble cryptophanes showing unprecedented affinity for xenon: Candidates as NMR-based biosensors. J. Am. Chem. Soc. 128, 6239-6246.
16. Gupta, B., Levchenko, T. S., and Torchilin, V. P. (2005) Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Delivery Rev. 57, 637-651.
17. Wright, L. R., Rothbard, J. B., and Wender, P. A. (2003) Guanidinium rich peptide transporters and drug delivery. Curr. Protein Pept. Sci. 4, 105-124.
18. Goun, E. A., Pillow, T. H., Jones, L. R., Rothbard, J. B., and Wender, P. A. (2006) Molecular transporters: Synthesis of oligoguanidinium transporters and their apphcation to drug delivery and real-time imaging. ChemBioChem 7, 1497-1515.
19. Goun, E. A., Shinde, R., Dehnert, K. W., Adams-Bond, A., Wender, P. A., Contag, C. H., and Franc, B. L. (2006) Intracellular cargo delivery by an octaarginine transporter adapted to target prostate cancer cells through cell surface protease activation. Bioconjugate Chem. 17, 787-796.
20. Sibrian-Vazquez, M., Jensen, T. J., Hammer, R. P., and Vicente, M. G. H. (2006) Peptide-mediated cell transport of water soluble porphyrin conjugates. J. Med. Chem. 49, 1364-1372.
21. Yang, J. H., Wang, K., Driver, J., Yang, J. H., and Barron, A. R. (2007) The use of fullerene substituted phenylalanine amino acid as a passport for peptides through cell membranes. Org. Biomol. Chem. 5, 260-266.
22. Belvisi, L., Bernardi, A., Colombo, M., Manzoni, L., Potenza, D., Scolastico, C., Giannini, G., Marcellini, M., Riccioni, T., Castorina, M., LoGiudice, P., and Pisano, C. (2006) Targeting integrins: Insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids. Bioorg. Med. Chem. 14, 169-180.
23. Harris, T. D., Kalogeropoulos, S., Nguyen, T., Liu, S., Bartis, J., Ellars, C., Edwards, S., Onthank, D., Silva, P., Yalamanchili, P., Robinson, S., Lazewatsky, J., Barrett, J., and Bozarth, J. (2003) Design, synthesis, and evaluation of radiolabeled integrin alpha(v)beta(3) receptor antagonists for tumor imaging and radiotherapy. Cancer Biother. Radiopharm. 18, 627-641.
24. Temming, K., Schiffelers, R. M., Molema, G., and Kok, R. J. (2005) RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Updates 8, 381-402.
25. Cescato, R., Schulz, S., Waser, B., Eltschinger, V., Rivier, J. E., Wester, H. J., Culler, M., Ginj, M., Liu, Q. S., Schonbrunn, A., and Reubi, J. C. (2006) Internahzation of sst(2), sst(3), and sst(5) receptors: Effects of somatostatin agonists and antagonists. J. Nucl. Med. 47, 502-511.
26. Ginj, M., Zhang, H. W., Waser, B., Cescato, R., Wild, D., Wang, X. J., Erchegyi, J., Rivier, J., Macke, H. R., and Reubi, J. C. (2006) Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc. Natl. Acad. Sci. U.S.A. 103, 16436-16441.
27. Reubi, J. C., Eisenwiener, K. P., Rink, H., Waser, B., and Macke, H. R. (2002) A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur. J. Pharmacol. 456, 45-49.
28. Hilgenbrink, A. R., and Low, P. S. (2005) Folate receptor-mediated drug targeting: From therapeutics to diagnostics. J. Pharm. Sci. 94, 2135-2146.
29. Byzova, T. V., Goldman, C. K., Pampori, N., Thomas, K. A., Bett, A., Shattil, S. J., and Plow, E. F. (2000) A mechanism for modulation of cellular responses to VEGF: Activation of the integrins. Mol. Cell 6, 851-860.
30. Byzova, T. V., Kim, W., Midura, R. J., and Plow, E. F. (2000) Activation of integrin alpha(v)beta(3) regulates cell adhesion and migration to bone sialoprotein. Exp. Cell Res. 254, 299-308.
31. Cairns, R. A., Khokha, R., and Hill, R. P. (2003) Molecular mechanisms of tumor invasion and metastasis: An integrated view. Curr. Mol. Med. 3, 659-671.
32. Felding-Habermann, B. (2003) Integrin adhesion receptors in tumor metastasis. Clin. Exp. Metastas. 20, 203-213.
33. Pierschbacher, M. D., Hayman, E. G., and Ruoslahti, E. (1985) The cell attachment determinant in fibronectin. J. Cell. Biochem. 28, 115-126.
34. Pierschbacher, M. D., and Ruoslahti, E. (1984) Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309, 30-33.
35. Ruoslahti, E. (2003) The RGD story: a personal account. Matrix Biol. 22, 459-465.
36. Ruoslahti, E., and Pierschbacher, M. D. (1986) Arg-Gly-Asp - a versatile cell recognition signal. Cell 44, 517-518.
37. Ye, Y. P., Bloch, S., Xu, B. G., and Achilefu, S. (2006) Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J. Med. Chem. 49, 2268-2275.
38. Gottschalk, K. E., and Kessler, H. (2002) The structures of Integrins and integrin-ligand complexes: Implications for drug design and signal transduction. Angew. Chem., Int. Ed. 41, 3767-3774.
39. Tornøe, C. W., Christensen, C., and Meldal, M. (2002) Peptidotriazoles on solid-phase: [1,2,3]-Triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org. Chem. 67, 3057-3064.
40. Punna, S., Kuzelka, J., Wang, Q., and Finn, M. G. (2005) Head-to-tail peptide cyclodimerization by copper-catalyzed azide-alkyne cycloaddition. Angew. Chem., Int. Ed. 44, 2215-2220.
41. Rostovtsev, V. V., Green, L. G., Fokin, V. V., and Sharpless, K. B. (2002) A stepwise Huisgen cycloaddition process: Copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew. Chem., Int. Ed. 41, 2596-2599.
42. Riddles, P. W., Blakeley, R. L., and Zerner, B. (1983) Reassessment of Ellman's reagent. Methods Enzymol. 91, 49-60.
43. Rouse, J. G., Yang, J. Z., Barron, A. R., and Monteiro-Riviere, N. A. (2006) Fullerene-based amino acid nanoparticle interactions with human epidermal keratinocytes. Toxicol. In Vitro 20, 1313-1320.
44. Lowery, T. J., Rubin, S. M., Ruiz, E. J., Spence, M. M., Winssinger, N., Schultz, P. G., Pines, A., and Wemmer, D. E. (2003) Applications of laser-polarized Xe-129 to biomolecular assays. Magn. Reson. Imaging 21, 1235-1239.
45. Lindgren, M., Gallet, X., Soomets, U., Hallbrink, M., Brakenhielm, E., Pooga, M., Brasseur, R., and Langel, U. (2000) Translocation properties of novel cell penetrating transportan and penetratin analogues. Bioconjugate Chem. 11, 619-626.
46. Lindgren, M., Hallbrink, M., Prochiantz, A., and Langel, U. (2000) Cell-penetrating peptides. Trends Pharmacol. Sci. 21, 99-103.
47. Zorko, M., and Langel, U. (2005) Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv. Drug Delivery Rev. 57, 529-545.
48. Haubner, R., Wester, H. J., Burkhart, F., Senekowitsch-Schmidtke, R., Weber, W., Goodman, S. L., Kessler, H., and Schwaiger, M. (2001) Glycosylated RGD-containing peptides, tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 42, 326-336.
49. Bolskar, R. D., Benedetto, A. F., Husebo, L. O., Price, R. E., Jackson, E. F., Wallace, S., Wilson, L. J., and Alford, J. M. (2003) First soluble M@C-60 derivatives provide enhanced access to metallofullerenes and permit in vivo evaluation of Gd@C-60[C(COOH)(2)](10) as a MRI contrast agent. J. Am. Chem. Soc. 125, 5471-5478.
50. Xu, J. Y., Li, Q. N., Li, J. G., Ran, T. C., Wu, S. W., Song, W. M., Chen, S. L., and Li, W. X. (2007) Biodistribution of Tc-99m-C-60(OH)(x) in Sprague-Dawley rats after intratracheal instillation. Carbon 45, 1865-1870.
51. Tabata, Y., and Ikada, Y. (1999) Biological functions of fullerene. Pure Appl. Chem. 71, 2047-2053.
52. Rostovtsev, V. V., Green, L. G., Fokin, V. V., and Sharpless, K. B. (2002) A stepwise Huisgen cycloaddition process: Copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew. Chem., Int. Ed. 41, 2596-2599.
53. Bendifallah, N., Rasmussen, F. W., Zachar, V., Ebbesen, P., Nielsen, P. E., and Koppelhus, U. (2006) Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA). Bioconjugate Chem. 17, 750-758.
54. Myrberg, H., Lindgren, M., and Langel, U. (2007) Protein delivery by the cell-penetrating peptide YTA2. Bioconjugate Chem. 18, 170-174.